戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 he preclinical sensitization stage (allergen immunoprophylaxis).
2 mab provides safe and effective, yet costly, immunoprophylaxis.
3 s as major strains seemed to be protected by immunoprophylaxis.
4 wly release bnAbs for long-term pre-exposure immunoprophylaxis.
5 tion strategies and consideration of passive immunoprophylaxis.
6 pecies of four MTCT pairs that broke through immunoprophylaxis.
7 nnessee Medicaid and eligible to receive RSV immunoprophylaxis.
8 ertain endemic regions as well as failure of immunoprophylaxis.
9 s with positive maternal HBsAg under current immunoprophylaxis.
10 e mechanism of action of polyclonal anti-KEL immunoprophylaxis.
11 ays in double-KO mice despite treatment with immunoprophylaxis.
12 alloreactivity despite the use of multiagent immunoprophylaxis.
13 cgammaRs and C3 became alloimmunized despite immunoprophylaxis.
14 m-targeted antileishmanial immunotherapy and immunoprophylaxis.
15 tants in RSV-breakthrough patients receiving immunoprophylaxis.
16 ycophenolate mofetil for posttransplantation immunoprophylaxis.
17 rapeutic approaches such as immunotherapy or immunoprophylaxis.
18 tter design strategies for immunotherapy and immunoprophylaxis.
19  will offer great clinical potential for RSV immunoprophylaxis.
20         Only 1 nonimmune respondent received immunoprophylaxis.
21 hysiologic injury led to renewed interest in immunoprophylaxis.
22 mg/kg of body weight), previously applied as immunoprophylaxis against antibiotic-resistant bacterial
23 t the potential importance of the capsule in immunoprophylaxis against cholera caused by V. cholerae
24 body IgG1 5H2 may prove valuable for passive immunoprophylaxis against dengue virus in humans.
25 ractive candidate for further development of immunoprophylaxis against DENV and perhaps other flavivi
26 posttransplant cyclophosphamide (Cy) as sole immunoprophylaxis against graft-versus-host disease (GVH
27                        Active and/or passive immunoprophylaxis against hepatitis C virus (HCV) remain
28 at could be exploited clinically for passive immunoprophylaxis against HIV-1.
29 -IL-10 antibody significantly improves Flt3L immunoprophylaxis against infection mediated by Th1-type
30                                   To develop immunoprophylaxis against intrapartum HIV-1 transmission
31       We expect that maternal vaccination or immunoprophylaxis against RSV will have a larger impact
32  alloreactivity that develops during ongoing immunoprophylaxis and identify 3 key transcriptional hal
33 st smallpox and may also be effective in the immunoprophylaxis and immunotherapy of smallpox and othe
34 st smallpox and may also be effective in the immunoprophylaxis and immunotherapy of smallpox.
35      Implications for vaccine design and for immunoprophylaxis and immunotherapy with a combination o
36 mune systems with important implications for immunoprophylaxis and immunotherapy.
37 g monoclonal antibody candidates for passive immunoprophylaxis and informs the rational design of hMP
38 ant human scFvs are potential candidates for immunoprophylaxis and therapy of flavivirus infections.
39 oresponse that occurs posttransplant despite immunoprophylaxis and to develop evidence-based strategi
40 lyclonal (CD4(+) and CD8(+)) T-cell lines as immunoprophylaxis and treatment for EBV-related lymphoma
41 st in developing these reagents for Ab-based immunoprophylaxis and treatment.
42                                 To date, RSV immunoprophylaxis and vaccine research is mainly focused
43 Current research into the development of new immunoprophylaxis and vaccines is mainly focused on the
44 splant recipients, 24 were administered HBIg immunoprophylaxis, and 28 were administered no specific
45 ategies such as infection control practices, immunoprophylaxis, and future vaccination programs.
46 A, the safety of withdrawing ERT, successful immunoprophylaxis, and justify continued clinical develo
47 other mammals for which specific therapy and immunoprophylaxis are unavailable.
48 IV vaccines or the bioaccumulation following immunoprophylaxis at the sites of HIV exposure.
49 antigen was chosen for study because passive immunoprophylaxis, based on gpA, has been shown to be pa
50                 This study demonstrates that immunoprophylaxis can mask subclinical infections, which
51 y more common among infants administered RSV immunoprophylaxis, compared with infants who did not rec
52                                     Vectored immunoprophylaxis could be of value for immunocompromise
53  immunoprophylaxis, elective conversion from immunoprophylaxis, de novo posttransplant HBV infection,
54                                          RSV immunoprophylaxis during infancy is efficacious in preve
55 prevent sexually-acquired HIV-1 infection by immunoprophylaxis, effective concentrations of broadly n
56 Recipient CD4+ T cells were not required for immunoprophylaxis efficacy at baseline, and modulation o
57 owing settings: failure of prolonged passive immunoprophylaxis, elective conversion from immunoprophy
58                  We classified children into immunoprophylaxis eligibility groups and calculated adhe
59                                 Adherence to immunoprophylaxis, follow-up testing rates, maternal ris
60 iform myeloablative conditioning regimen and immunoprophylaxis for graft-versus-host disease (GVHD).
61 evelop a long-lasting approach that provides immunoprophylaxis for mutation carriers.
62  the future development of immunotherapy and immunoprophylaxis for TB disease.
63  participating in a phase 3 trial of passive immunoprophylaxis for the prevention of perinatal transm
64  of vorinostat, in combination with standard immunoprophylaxis, for prevention of GVHD in patients un
65                        The implementation of immunoprophylaxis has been challenging, especially in lo
66 er clinically stable patients receiving HBIg immunoprophylaxis have detectable viral products in thei
67                                      Despite immunoprophylaxis, hepatitis B virus (HBV) transmission
68 expressed antibodies show promise as passive immunoprophylaxis in a breastfeeding model in newborns.
69 ing recovery from infection, indicating that immunoprophylaxis in cats might be beneficial in helping
70                    This investigation of RSV immunoprophylaxis in high-risk children primarily found
71                       Here, we used vectored immunoprophylaxis in humanized mice to interrogate the e
72 We investigated whether greater adherence to immunoprophylaxis in infants at high risk for severe RSV
73 or timing the use of future RSV vaccines and immunoprophylaxis in low- and middle-income countries.
74 emonstrates the potential of anti-HIV IgA in immunoprophylaxis in vivo, emphasizing the importance of
75             The strict definition of passive immunoprophylaxis includes the administration of exogeno
76 medical center of this study, high-dose HBIg immunoprophylaxis is administered at a fixed dose of 10,
77                             Passive antibody immunoprophylaxis is one method used to protect patients
78 r effective treatment, with the exception of immunoprophylaxis, is available for this infection as we
79                          Polyclonal anti-KEL immunoprophylaxis (KELIg) was administered to wild-type
80 ead to breakthrough alloimmunization despite immunoprophylaxis may have translational relevance to in
81             Suppressing RSV infection by RSV immunoprophylaxis might increase the risk of having HRV
82  and its F(ab')2 derivative in an intranasal immunoprophylaxis model, we determined that Fc-mediated
83  example, we discuss the advances in passive immunoprophylaxis, most notably the shift from the recom
84                                 Despite full immunoprophylaxis, mother-to-child transmission (MTCT) o
85 ance in clinical RSV isolates collected from immunoprophylaxis-naive subjects.
86            KZ52 is a promising candidate for immunoprophylaxis of Ebola virus infection.
87 nd the only licensed intervention is passive immunoprophylaxis of high-risk infants with a humanized
88 ous agent supports assessment of rhIL-12 for immunoprophylaxis of human malaria.
89 hese findings support a role for DbpA in the immunoprophylaxis of Lyme disease and suggest that DbpA
90 sulfan (3.2 mg/kg daily for 2 days) and GVHD immunoprophylaxis of mycophenolate mofetil (1 g three ti
91 nd E7 genes can be an effective strategy for immunoprophylaxis of papillomavirus infection.
92  critical determinant for both diagnosis and immunoprophylaxis of the hepatitis B virus.
93 tenance are therefore attractive targets for immunoprophylaxis or chemotherapy.
94    Up to 3 years, no adverse sequelae of the immunoprophylaxis or clinical and ex vivo recurrent auto
95 n targeted by protective antibodies (Abs) in immunoprophylaxis or elicited by vaccination.
96                                      Passive immunoprophylaxis or immunotherapy with norovirus-neutra
97 The mAbs were expressed in vivo via vectored immunoprophylaxis or recombinantly.
98  monoclonal antibodies may provide effective immunoprophylaxis or therapy against BoNT/A intoxication
99 tions targeting respiratory viruses, such as immunoprophylaxis or vaccines for RSV and influenza, may
100 s, compared with infants who did not receive immunoprophylaxis (OR, 1.65; 95% CI, 1.65-2.39).
101 g during the period of protection offered by immunoprophylaxis ("preventable fraction") under the AAP
102 uld have implications for the development of immunoprophylaxis programs in humans.
103 s the more restrictive age thresholds in RSV immunoprophylaxis recommendations.
104  at high risk of HIV-1 transmission, such an immunoprophylaxis regimen could have a major impact on v
105 nd regional adjustments to the timing of the immunoprophylaxis regimen.
106 V transmission worldwide despite an existing immunoprophylaxis regimen.
107 me model to estimate protection conferred by immunoprophylaxis regimens with alternate start dates, b
108  development of vaccines, immunotherapy, and immunoprophylaxis regimens.
109 id neutralizing epitope of 80R, an effective immunoprophylaxis strategy with 80R should be possible i
110  more robust human immune competent mice for immunoprophylaxis studies.
111 ipients receiving cyclosporine-based primary immunoprophylaxis suffer higher rates of allograft rejec
112         After conventional myeloablation and immunoprophylaxis, the treated donor cells were transfus
113 tiviral responses may impact the efficacy of immunoprophylaxis therapy in a type 1 interferon (IFN)-d
114   Prednisone (60 mg/day) was administered as immunoprophylaxis through week 4, followed by an 11-week
115 or Disease Control and Prevention recommends immunoprophylaxis to decrease perinatal transmission.
116 successfully retransplanted using aggressive immunoprophylaxis to prevent HBV reinfection.
117 fumarate (TDF) therapy accompanied by infant immunoprophylaxis to prevent hepatitis B virus (HBV) mot
118 action, we have now evaluated the outcome of immunoprophylaxis treatment in mice lacking Fcgamma rece
119 ecently demonstrated the ability of vectored immunoprophylaxis (VIP) to prevent intravenous transmiss
120                        We have used vectored immunoprophylaxis (VIP), an adeno-associated virus-based
121 ion of this approach, which we call vectored immunoprophylaxis (VIP), which in mice induces lifelong
122 cond case, hepatitis B immunoglobulin (HBIG) immunoprophylaxis was administered in an attempt to prev
123                  AAV and lentiviral vectored immunoprophylaxis was durable and was active against SAR
124                                     Vectored immunoprophylaxis was first developed as a means of esta
125  the combined group, higher adherence to RSV immunoprophylaxis was not associated with decreased asth
126  No significant antigenic drift compromising immunoprophylaxis was observed.
127 tients who received tacrolimus-based primary immunoprophylaxis were enrolled in this prospective, obs
128  5.8 years) who did not respond to postnatal immunoprophylaxis were prospectively followed for 1-22.8
129 at extremely low risk for transmission after immunoprophylaxis who are unlikely to benefit from furth
130 he American Academy of Pediatrics recommends immunoprophylaxis with a series of up to 5 injections of
131                                              Immunoprophylaxis with glucan phosphate increased (p <.0
132   Most patients underwent aggressive passive immunoprophylaxis with HBIg to maintain serum HBV surfac
133    However, with the introduction of passive immunoprophylaxis with hepatitis B immunoglobulin and tr
134 ections via MTCT include underutilization of immunoprophylaxis with hepatitis B vaccination and hepat
135                                              Immunoprophylaxis with hyperimmune globulin or with a hu
136  breastmilk; and active (vaccine) or passive immunoprophylaxis with long-acting broadly neutralising
137                                              Immunoprophylaxis with palivizumab (Synagis), a humanize
138                            Thus, combination immunoprophylaxis with passively administered synergisti
139 previously described a murine model in which immunoprophylaxis with polyclonal anti-KEL sera prevents
140 d-type and single-KO recipients treated with immunoprophylaxis, with the transfused RBCs remaining in
141  Thus, synergistic MAbs protect when used as immunoprophylaxis without the prenatal dose.

 
Page Top